solid tumor Articles
-
Ozette’s computationally-driven analysis aids advancement of cancer drug development - Case study
Summary Inflammation is a hallmark of the tumor microenvironment and an area of active investigation. To better understand how tumor inflammation differs from general inflammation, such as in gum disease, Drs. Prilic, Mair, and Erikson employed novel methods, which included high parameter flow cytometry and Ozette’s foundational technology–full annotation using ...
-
First-in-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP inhibitor, in Patients with Advanced Solid Tumors
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors known as single-strand breaks. PARP inhibitors are currently approved (or ovary, breast, pancreatic and prostate cancers which harbor BRCA1/2 mutations and/or homologous recombinant repair mutation. In this phase 1 dose escalation study of venadaparib, we determined the maximum tolerated dose ...
-
Celdara Medical Receives National Institutes of Health Funding to develop a new CAR T cell platform to treat solid tumors
Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) Phase I award to fund the company’s proof of concept studies on a new platform to improve chimeric antigen receptor (CAR) T cells efficacy to treat solid tumors. Dr. Joana Murad-Mabaera, who leads this effort, stated, ...
-
Effect of interferon receptor pathway on CAR-T cell-mediated killing of solid tumors
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
-
A Novel Potential Target for CAR-T Cell Therapy in Human Solid Tumors Discovered
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
-
Cytotoxicity of activated natural killer cells against pediatric solid tumors
Abstract Purpose: To develop new therapies for children with solid tumors, we tested the cytotoxicity of natural killer (NK) cells expanded by coculture with K562-mb15-41BBL cells. We sought to identify the most sensitive tumor subtypes, clarify the molecular interactions regulating cytotoxicity, and determine NK antitumor potential in vivo. Experimental design: We tested in vitro ...
By Nkarta, Inc.
-
Novel, Smaller and More Powerful CTLA4 Inhibitors for the Treatment of Solid Tumors
Abstract Immune checkpoint inhibitors (ICIs) have obtained durable responses in many cancers, making it possible to foresee their potential in improving the health of cancer patients. However, immunotherapies are limited at the moment to a minority of patients and there is a need for a better understanding of the basic molecular mechanisms and functions of pivotal immune molecules. Immune ...
-
Natural Killer Cells May Be Scaled and Engineered as a Next Generation, Off-the-Shelf Cell Therapy for Cancer
The advent of immunotherapies for cancer, and more recently of cellular immunotherapies, has substantially altered the treatment landscape. In hematological malignancies, complete response rates to CAR-T cells can exceed 80%. These responses are often durable in nature and have attracted considerable excitement and investment in the development of cell therapies for an expanded range of ...
By Nkarta, Inc.
-
CAR-T Cell Anti-Cancer Therapy Ushered in A Revolutionary Breakthrough!
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. In particular, CAR-T therapy, which has been approved by the FDA, is rewriting the treatment paradigm of some hematological tumors. However, adoptive T cell therapy remains of little success in solid tumors. The main reason is that ...
-
Idience: developing selective and potent PARP inhibitor IDX-1197 for solid tumors
The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and overcome resistance. The company plans to target homologous recombination repair-proficient patients with a clinical-phase PARP inhibitor that is now available for licensing. Ildong Holdings, a major ...
-
A Plant Immune Protein May be Expected to Completely Cure Cancer!
Cancer, caused by abnormal cell proliferation, is one of the world's major public health problems. Recently, in a research report entitled "A plant immune protein enables broad antitumor response by rescuing microRNA deficiency" published in Cell, Scientists from institutions such as Peking University have found that a special plant immune protein may achieve a broad spectrum of anti-tumor ...
-
Derivation of low-dose extrapolation factors from analysis of curvature in the cancer incidence dose response in Japanese A-bomb survivors
The derivation of cancer risks after low-dose and low-dose-rate exposure to ionising radiation is critical to the setting of standards for radiological protection. In extrapolating cancer risks observed in groups exposed at a high dose-rate such as the Japanese A-bomb survivors, the International Commission on Radiological Protection (ICRP) recommends application of a Dose and Dose-Rate ...
-
Three generations of ADC: Nearly a decade of development-PII
Kadcyla and second-generation non-cleavable linkers Alternative linker design methodologies are still under development. Immunogen discovered a very powerful ADC by an accidental discovery. The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in ...
-
How to Design a Good ADC Drug
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
By BOC Sciences
-
Tapping into the drug discovery potential of AI
Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development. In April of this year, the German biotechnology company Evotec announced a phase 1 clinical trial on a new anticancer molecule. The candidate was created in partnership with Exscientia, a company based in Oxford, UK, that applies ...
By Iktos
-
The Tumor Marker: Vascular Endothelial Growth Factor 165 (VEGF165)
Tumors and Blood Vessel Growth Tumor, as an abnormal mass of cells, has blood vessels of various sizes that can be seen everywhere on the surface and deep within it. Nutrients for life are continuously supplied to the depths of tumor cells through these blood vessels. As the tumor continues to grow, nearby blood vessels also undergo rapid and chaotic growth, with these newly formed capillaries ...
-
Analytical Approaches and Applications of Whole Exome Sequencing (WES) in Oncology
Introduction Genomics has revolutionized cancer research, transforming the way we diagnose, treat, and monitor cancer. Among the powerful genetic analysis methods, Whole Exome Sequencing (WES) stands out as a cutting-edge technique that employs sequence capture technology to enrich DNA from the whole exome regions, enabling high-throughput sequencing. WES offers a simpler, more cost-effective, ...
By CD Genomics
-
Cancer Target: Mesothelin
Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment. In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis ...
-
ODS Medical is a 2018 Medtech Innovator Showcase Company
Summary: In treating brain cancers, neurosurgeons face a critical decision: remove too little tissue and risk fatal recurrences or remove too much and cause profound neurological damage. Presently, they rely on pre-operative surgical navigation technologies, such as MRI, in order to determine the contours of the cancerous tissue to be safely removed. These surgical navigation systems, in ...
-
An Emerging Aim: ADC Target Protein - Nectin-4
The biologics license application (BLA) has been accepted for Enfortumab Vedotin for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have previously received PD-1/PD-L1 inhibitors and platinum-containing chemotherapy. Enfortumab Vedotin is the first domestically submitted targeted antibody-drug conjugate that specifically targets Nectin-4. Enfortumab ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you